Early and Consistent Weight Loss Linked to Poorer Outcomes in ALS, Study Suggests

The rate of weight loss from onset to diagnosis can be a significant indicator of poorer outcomes among amyotrophic lateral sclerosis (ALS) patients, a study reports. The study, “Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort,” was published in the…

A human-derived antibody that specifically binds to abnormal superoxide dismutase 1 (SOD1) improved the symptoms and delayed disease progression in a mouse model for amyotrophic lateral sclerosis (ALS), a study shows. The antibody, alpha-miSOD1, could be further developed as a candidate treatment for ALS caused by SOD1 misfolding. The study titled…

In addition to symptoms of depression, disease progression is one of the strongest influences on health-related quality of life in amyotrophic lateral sclerosis (ALS) patients, a study reports. According to the study, titled Disease progression impacts health-related quality of life in amyotrophic lateral sclerosis,” slower disease progression is linked to…

CuATSM, one of the lead investigational therapies of Collaborative Medicinal Development (CMD), may slow disease progression and improve the respiratory and cognitive function of patients with amyotrophic lateral sclerosis (ALS), a Phase 1 trial shows. The findings of the multicenter, open-label, dose-finding study (NCT02870634) were announced by…

“Reports of my demise have been greatly exaggerated.” —Mark Twain, in a letter to The New York Sun I spent the better part of November under the weather. I am always taken aback by the “uncommon” havoc the “common” cold can wreak on someone with the deficit baseline…

EnClear Therapies, a biotech company developing a device to halt the progression of neurological diseases including amyotrophic lateral sclerosis (ALS), announced it has spun out from QurAlis, one of its founding companies.

The new year is just beginning, and my email inbox is already overflowing with suggestions about the importance of setting goals and resolutions. But for many living with ALS, traditional goals and resolutions for self-improvement can feel empty and useless. In truth, most of us are just…

CloudMedx plans to develop a computer analysis algorithm that will track the clinical progression of patients with amyotrophic lateral sclerosis (ALS) to predict treatment outcomes. This tool will be the result of a new collaboration between the healthcare artificial intelligence (AI) company and the Gregory W. Fulton…

When I look back at 2018, I feel pride. I fought my ALS hard. I forced myself to finish all my meals, even when I had zero appetite, to minimize weight loss. I made it to all my appointments, though I had to reschedule multiple times. I asked…

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Revalesio’s experimental therapy RNS60 for people diagnosed with amyotrophic lateral sclerosis (ALS). A phase 2 trial is now recruiting participants. Fast Track designation is intended to shorten the time it takes for the…